NEWCASTLE UPON TYNE, UK 13 December, 2022. QuantuMDx Group Limited (“QuantuMDx”), today announces that its Q-POC™ SARS-CoV-2, Flu A/B & RSV Assay, has been approved for sale in the UK under The Medical Devices (Coronavirus Test Device Approvals) (Amendment)...
Preventing Antimicrobial Resistance Together Antimicrobial resistance (AMR) describes the situation when microorganisms (bacteria, fungi, parasites and viruses) no longer respond to the drugs (antimicrobials) that are used to treat infections. As a consequence,...
Agreement will initially cover the UK and France with potential to expand to other European countries and worldwide NEWCASTLE UPON TYNE, UK, 2 November 2022. QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point of Care molecular...
The agreement sets a roadmap for the commercialisation of Q-POC™ and its assays in China The two companies will collaborate to accelerate the development of new assays on the Q-POC™ platform Offers potential for component sourcing and manufacturing optimisation...
Andy Whittle, VP Manufacturing at QuantuMDx, discusses the highs and lows of scaling up to manufacture, during a global pandemic. What is your background? I've over 20 years manufacturing experience, focusing primarily within life science and medical devices. I...
Sam Bhatt is a Programme Manager at QuantuMDx. Here, Sam tells us more about himself and gives us an insight into his role. When did you start working at QuantuMDx? I joined the QuantuMDx team in May 2015, not long after I completed my PhD (in radiotracers for...